ChemPartner’s Drug Metabolism Pharmacokinetic (DMPK) and Exploratory Toxicology department consists of in vitro ADME, pharmacokinetics (PK), non-GLP toxicology, and bioanalytical (GLP and non-GLP) function groups. Our leadership team, drawing on experience from world-renowned pharmaceutical companies, emphasizes a science-based culture and executes quality DMPK/toxicology studies as well as integrates DMPK/toxicology data into our biopharmaceutical clients’ discovery programs. DMPK/exploratory tox department also conducts studies for many pharmaceutical and biotech clients in support of their regulatory filings.
Since 2007, extensive ADME profiling (80,000+) and PK and exploratory toxicology studies (50,000+) have been conducted to support numerous drug discovery and development programs with our worldwide partners. Working closely with ChemPartner’s internal biology/pharmacology, and antibody engineering teams, our DMPK group supports translational medicine through our expertise in formulation development, in vitro-in vivo extrapolation, PK/PD modeling, biomarker analysis, and metabolomics.
We take pride in our work and view our partners’ success as our success.
